tiprankstipranks
Integer Holdings (ITGR)
NYSE:ITGR
US Market
Want to see ITGR full AI Analyst Report?

Integer Holdings (ITGR) Earnings Dates, Call Summary & Reports

153 Followers

Earnings Data

Report Date
Jul 23, 2026
Before Open (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
1.38
Last Year’s EPS
1.55
Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings

Earnings Call Summary

Q1 2026
Earnings Call Date:Apr 30, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call conveyed a mixed picture: a modest top-line improvement in Q1 (reported +0.5%, organic +1.3%) and several strategic positives (share buybacks, lower interest expense, targeted cost actions, pipeline strength and a Board-initiated strategic review) were offset by meaningful near-term profitability pressures (adjusted operating income down 14%, margin contraction of 230 bps), weaker cash flow in Q1, and a downward revision to full-year 2026 revenue and profit guidance. Management characterizes the demand softness—primarily in electrophysiology—as temporary normalization and emphasized actions to protect long-term growth, but the guidance cuts and margin contraction represent notable near-term headwinds.
Company Guidance
Integer updated its 2026 guidance with full‑year reported sales now expected at $1.805–$1.835 billion (down 1%–3% YoY) and organic sales flat to down 1% (including a ~3%–4% headwind from three new products; organic growth excluding those products ~3%–4%); inorganic decline ~1% (Portable Medical exit); C&V expected flat to down low‑single digits, CRM&N flat to up low‑single digits, and other markets down ~$34M–$36M. Profitability outlook: adjusted EBITDA $375M–$399M (down 1%–7%), adjusted operating income $285M–$305M (down 5%–11%) with sequential margin improvement expected (Q2 operating margin +80–140 bps and continuing improvement through 2026), adjusted net income $200M–$220M (down 3%–11%) and adjusted EPS $5.83–$6.40 (flat to down 9%). Cash/debt targets: cash flow from operations $185M–$205M (≈$15M lower at midpoint), CapEx $95M–$105M (~5%–6% of sales), free cash flow $85M–$105M, year‑end net total debt $1.185B–$1.205B and leverage expected in the 2.5x–3.5x trailing‑4Q adjusted EBITDA target range (Q1 net total debt $1.264B, leverage 3.2x). Q1 actuals and drivers: sales $440M (+0.5% reported, +1.3% organic), adjusted EBITDA $85M (‑7%), adjusted operating margin 13.9% (‑230 bps), adjusted net income $41M (‑10%), adjusted EPS $1.20 (‑8%), cash from ops $25M, CapEx $24M, free cash flow $1M; interest expense was $4M lower (helping EPS by ~$0.10), and share repurchases of $50M in Q4 ’25 (~700k shares) and $50M in Q1 ’26 (~600k shares) reduced weighted shares ~2% (adding ~$0.02 to EPS).
Quarterly Revenue Growth
Q1 2026 sales of $440 million, up 0.5% on a reported basis and up 1.3% on an organic basis versus the prior year.
Strength in Core Product Lines (C&V and CRM&N)
Cardio & Vascular sales of $262 million, up 1% in Q1 and up 13% on a trailing 4-quarter basis to $1.110 billion driven by EP, acquisitions and Neurovascular demand. Cardiac Rhythm Management & Neuromodulation sales of $168 million, up 5% in Q1; trailing 4-quarter CRM&N sales up 2% to $677 million.
Earnings Per Share Benefited from Lower Interest and Buybacks
Adjusted EPS of $1.20 in Q1; benefited from $4 million lower interest expense (added approximately $0.10 per share) and share repurchases (completed $50 million in Q4 2025 and $50 million in Q1 2026, reducing weighted average shares ~2% and adding ~$0.02 to EPS).
Targeted Cost Actions and Margin Recovery Plan
Company is implementing additional near-term cost reduction actions (designed not to compromise customer service or long-term growth) and expects Q2 adjusted operating income margin to improve 80–140 basis points sequentially with margins improving throughout 2026.
Balance Sheet Discipline and Leverage in Target Range
Net total debt of $1.264 billion (up $74 million QoQ) yields a net total debt leverage of 3.2x trailing 4-quarter adjusted EBITDA, which is inside the company’s strategic target range of 2.5x–3.5x.
Strategic Review Initiated to Maximize Shareholder Value
Board initiated a strategic review in response to heightened interest; review may consider a range of alternatives while management reiterates confidence in the stand‑alone strategy and long-term objectives.
Long-Term Market Position and Pipeline
Management reiterates confidence in attractive med-tech end markets (target market growth 4%–6%), a robust new product pipeline and the expectation to return to organic sales growth ~200 basis points above market in 2027.
Cash Deployment and Capital Plan
Continued share repurchases (totaling ~$100 million across Q4 2025 and Q1 2026) and guidance for 2026 CapEx of $95–105 million (~5%–6% of sales), with expected free cash flow of $85–105 million for the year.

Integer Holdings (ITGR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ITGR Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Jul 23, 2026
2026 (Q2)
1.38 / -
1.55
Apr 30, 2026
2026 (Q1)
1.19 / 1.20
1.31-8.40% (-0.11)
Feb 19, 2026
2025 (Q4)
1.70 / 1.76
1.4323.08% (+0.33)
Oct 24, 2025
2025 (Q3)
1.69 / 1.79
1.4325.17% (+0.36)
Jul 24, 2025
2025 (Q2)
1.55 / 1.55
1.319.23% (+0.25)
Apr 24, 2025
2025 (Q1)
1.23 / 1.31
1.1414.91% (+0.17)
Feb 20, 2025
2024 (Q4)
1.46 / 1.43
1.392.88% (+0.04)
Oct 24, 2024
2024 (Q3)
1.36 / 1.43
1.2712.60% (+0.16)
Jul 25, 2024
2024 (Q2)
1.23 / 1.30
1.1414.04% (+0.16)
Apr 25, 2024
2024 (Q1)
1.11 / 1.14
0.8731.03% (+0.27)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ITGR Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Apr 30, 2026
$83.67$88.51+5.78%
Feb 19, 2026
$86.48$83.00-4.02%
Oct 24, 2025
$73.89$72.91-1.33%
Jul 24, 2025
$115.77$107.10-7.49%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Integer Holdings (ITGR) report earnings?
Integer Holdings (ITGR) is schdueled to report earning on Jul 23, 2026, Before Open (Confirmed).
    What is Integer Holdings (ITGR) earnings time?
    Integer Holdings (ITGR) earnings time is at Jul 23, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ITGR EPS forecast?
          ITGR EPS forecast for the fiscal quarter 2026 (Q2) is 1.38.